AI assistant
Nuvectis Pharma, Inc. — Director's Dealing 2025
Nov 6, 2025
33912_dirs_2025-11-06_b6ab4746-50f7-4170-a08e-e537018cea27.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2025-11-05
Reporting Person: Kaplan Matthew L. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Common Stock | P | 11000 | $5.84 | Acquired | 124760 | Direct |
Footnotes
F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.